课题基金 / 基金详情

Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas

Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
探索联合治疗肾透明细胞癌的新治疗策略
批准号:
10608244
负责人:
Weizhou Zhang
金额:
$50.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-01-01 至 2027-12-31
关键词:
AgeAgingAutoimmunityBCL2L1 geneBloodCD8-Positive T-LymphocytesCancer ModelCancer PatientCell AgingCell ProliferationCellsChemicalsChronicClear cell carcinomaClear cell renal cell carcinomaClinicalConventional (Clear Cell) Renal Cell CarcinomaDataDevelopmentDevelopmental ProcessDiagnosisDrug resistanceExhibitsGeneticHistologicHumanImmuneImmune checkpoint inhibitorImmunosuppressionIn complete remissionInduction of ApoptosisInfiltrationKidneyLabelLeadLiteratureMalignant NeoplasmsMutationNeoplasm MetastasisOncogene ActivationOncogenesOrganOutcomePathogenesisPatientsPharmaceutical PreparationsPhenotypePlayPopulationProcessPrognosisProtacPublicationsRadiation therapyRegimenRegulatory T-LymphocyteRenal Cell CarcinomaRenal carcinomaReportingResearchResistanceRoleSpecimenT cell infiltrationTechnologyTherapeuticTherapeutic InterventionTracerTreatment EfficacyTreatment ProtocolsTumor ImmunityTumor PromotionTumor-associated macrophagesUbiquitinationUpdateWomanWorkaging populationangiogenesisantiangiogenesis therapybcl-xlong proteinbeta-Galactosidasecancer immunotherapycancer therapycancer typecarcinogenesiscellular targetingcheckpoint therapychemotherapydesigndrug developmenteffector T cellefficacy evaluationfightinghuman RNA sequencingimmune cell infiltrateimmunoregulationin vivoin vivo Modelmanmulticatalytic endopeptidase complexnormal agingnovelnovel therapeutic interventionpreventprognosis biomarkerrational designsenescencesingle-cell RNA sequencingtumortumor immunologytumor microenvironmenttumor progressiontumor-immune system interactionsubiquitin-protein ligase

项目摘要

项目成果

Weizhou Zhang的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要-摘要 肾细胞癌(RCC)是男性(第6位)和女性(第8位)中10种最常见的癌症类型之一。 国际吧大多数肾细胞癌是透明细胞癌(>80%),在许多方面代表非典型癌症类型 包括对许多化学治疗剂的内在抗性、对抗新血管生成的敏感性和抗肿瘤药物的敏感性。 免疫检查点抑制剂,但具有非常低的突变负担。RCC的治疗前景一直是 在过去几年中迅速变化,但即使在最严重的情况下, 更新治疗方案。RCC的这些“非典型”特征促使我们进行全面的单 人ccRCC和配对血液的细胞RNA测序。我们发现,肿瘤诱导的TdR是高度 抑制效应T细胞,可能是赋予免疫抑制性肿瘤的主要免疫细胞 微环境(TME)。这些TI-T细胞具有细胞衰老的典型迹象,包括表达 p16、p21、BCL-XL、衰老相关分泌表型(SASP)和β-半乳糖苷酶的激活 (β-Gal)。该小组最近报告了一流的BCL-XL降解剂的开发,即蛋白水解 靶向嵌合体(PROTAC,称为BCL-XL-Ps)。DT 2216,一种BCL-XL-P电极导线,将BCL-XL定位于 von Hippel-Lindau(VHL)E3连接酶;并且PZ 15227将BCL-XL靶向cereblon(CRBN)E3连接酶, 泛素化和随后的蛋白酶体降解。我们发现这两个senolytics是非常 在我们最近出版物中有效地消除TI-T细胞并激活抗肿瘤免疫。根据这些小说 研究发现,我们假设衰老和癌症相关的细胞衰老-包括衰老, 免疫细胞-通过调节肿瘤免疫在RCC发病机制和癌症进展中至关重要 微环境理解这些基本问题对于合理设计治疗方案是重要的。 治疗RCC的方案仍然是一个紧迫和未满足的临床需求。具体目标1是建立 细胞衰老-特别是Treg衰老-与具有特殊 关注肿瘤免疫微环境的调节。目的2是确定 T1-T细胞的衰老清除和RCC中的常用治疗。该团队拥有临床肾癌方面的专业知识, 细胞衰老,特别是衰老药物开发和衰老追踪,癌症模型, 癌症免疫学我们将确定肿瘤浸润性T细胞在肿瘤内免疫调节中的作用, 微环境,并确定靶向衰老THBE在RCC癌症治疗中的功效,通过结合 抗新生血管药物或免疫检查点抑制剂。
英文摘要
Project Summary-Abstract Renal cell carcinomas (RCC) are among the 10 most common cancer types in man (6th) and woman (8th) worldwide. Most RCC are clear cell carcinomas (>80%) that represent an atypical cancer type in many ways including the intrinsic resistance to many chemotherapeutics, sensitivity to anti-neoangiogenesis, and sensitivity to immune checkpoint inhibitors but with very low mutational burden. The treatment landscape of RCC has been changing rapidly in the last couple of years but still with very low complete response rate even with the most updated treatment regimens. Those “atypical” features of RCC prompted us to perform a comprehensive single cell RNA sequencing for human ccRCCs and paired bloods. We found that tumor induced Tregs are highly suppressive to effector T cells and could be the major immune cells conferring the immune suppressive tumor microenvironment (TME). These TI-Tregs have the typical signs of cellular senescence, including the expression of p16, p21, BCL-XL, senescence-associated secretory phenotype (SASP), and the activation of β-galactosidase (β-Gal). The group recently reported the development of the first-in-class BCL-XL degraders, i.e. the Proteolysis Targeting Chimeras (PROTACs, referred to as BCL-XL-Ps). DT2216, a lead BCL-XL-P, targets BCL-XL to the von Hippel-Lindau (VHL) E3 ligase; and PZ15227 targets BCL-XL to the cereblon (CRBN) E3 ligase for ubiquitination and subsequent degradation by the proteasome. We have found these two senolytics are very effective in eliminating TI-Tregs and activate anti-tumor immunity in our recent publication. Based on these novel findings, we hypothesize that aging- and cancer-associated cellular senescence – including senescence from immune cells – is critical in RCC pathogenesis and cancer progression via modulating the tumor immune microenvironment. Understanding these fundamental questions is important for rational design of therapeutic regimens towards to RCC that remains an urgent and unmet clinical need. Specific Aim 1 is to establish the mechanistic connection between cellular senescence – in particular Treg senescence – and RCC with special focus on the modulation of tumor immune microenvironment. Aim 2 is to determine the therapeutic efficacy of senolytic depletion of TI-Tregs and common therapeutics in RCC. The team has expertise in clinical renal cancer, cellular senescence, in particular the senolytic drug development and senescence tracing, cancer models and cancer immunology. We will establish the role of tumor infiltrating Tregs in immune modulation within the tumor microenvironment and determine the efficacy of targeting senescent Tregs in RCC cancer therapy, by combining with anti-neoangiogenesis drugs or immune checkpoint inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CD177 suppresses breast-cancer development by inhibiting beta-catenin
  • 批准号:
    10004577
  • 项目类别:
  • 资助金额:
    $34.2万
  • 财政年份:
    2016
  • 负责人:
    Weizhou Zhang
  • 依托单位:
Obesity, inflammation and breast cancer
  • 批准号:
    9003551
  • 项目类别:
  • 资助金额:
    $34.58万
  • 财政年份:
    2015
  • 负责人:
    Weizhou Zhang
  • 依托单位:
Myofibroblasts, T cells and malignant cells interplay in breast cancer metastasis
  • 批准号:
    8481645
  • 项目类别:
  • 资助金额:
    $24.9万
  • 财政年份:
    2012
  • 负责人:
    Weizhou Zhang
  • 依托单位:
Myofibroblasts, T cells and malignant cells interplay in breast cancer metastasis
  • 批准号:
    8523028
  • 项目类别:
  • 资助金额:
    $23.06万
  • 财政年份:
    2012
  • 负责人:
    Weizhou Zhang
  • 依托单位:
海外基金